(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

NCT05767879 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage III
In-Transit Metastasis of Cutaneous Melanoma

Interventions

DRUG: Encorafenib + Binimetinib

Sponsor

Leiden University Medical Center

Collaborators

[object Object]